Updates provided on deucrictibant, a potential HAE medicine currently being trialed in patients
A series of updates on deucrictibant, which is currently undergoing testing amongst HAE patients, were provided by the pharmaceutical company Pharvaris. The key updates shared were:
- Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025
- Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026
- Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) attacks, on track; study is expected to initiate by YE2025
Berndt Modig, Chief Executive Officer of Pharvaris, said: “Halfway through 2025, an important executional year for the company, Pharvaris is making meaningful progress in our ambition to address unmet needs of people living with bradykinin-mediated angioedema. The readout of RAPIDe-3 topline results, which is estimated to be in the fourth quarter of this year, is anticipated to be an important inflection point for our stakeholders. CHAPTER-3 continues to progress with topline results expected in the second half of 2026, and we are on track to initiate CREAATE in 2025.”
(Source: Pharvaris)